Table 2.
Characteristic | <25% of Remaining Life Spent Hospitalized (n = 3906) | 25%–100% of Remaining Life Spent Hospitalized (n = 991) | P |
---|---|---|---|
Age at diagnosis, y | <.001 | ||
64 to ≤74 | 54.1 | 43.5 | |
75 to ≤84 | 38.4 | 48.1 | |
85+ | 7.6 | 8.4 | |
Gender | .967 | ||
Male | 51.5 | 51.5 | |
Female | 48.5 | 48.5 | |
Race/ethnicity | .005 | ||
White, non-Hispanic | 88.9 | 85.8 | |
Hispanic | 5.5 | 6.2 | |
Black | 3.2 | 5.9 | |
Asian | 1.5 | 1.1 | |
Other | 0.9 | 1 | |
Marital status | .002 | ||
Married | 61.6 | 56.6 | |
Unmarried | 12.1 | 12.7 | |
Unknown | 26.3 | 30.7 | |
Comorbidity score | <.001 | ||
0 | 63.5 | 52.6 | |
1 | 25.2 | 27.1 | |
2+ | 11.4 | 20.3 | |
Year of diagnosis | .816 | ||
1999–2001 | 27.4 | 27.1 | |
2002–2004 | 36.5 | 36.4 | |
2005–2007 | 36.1 | 36.4 | |
Census tract income | .856 | ||
Lower income (<median) | 34.2 | 35.5 | |
Higher income (>median) | 65.8 | 64.5 | |
SEER registry region | .06 | ||
Northeast | 7.3 | 6.4 | |
South | 10.7 | 8.9 | |
Midwest | 15.5 | 18.4 | |
West | 66.5 | 66.4 | |
Tumor extent | .046 | ||
1 brain lobe | 75.4 | 71.9 | |
2+ brain lobes | 18 | 21.3 | |
Unknown | 6.6 | 6.9 | |
Surgery | <.001 | ||
Extensive (GTR) | 27.4 | 19.4 | |
Limited (biopsy/STR) | 72.6 | 80.6 | |
Radiotherapy delivered | <.001 | ||
Yes | 77.9 | 57.8 | |
No | 22.1 | 42.2 | |
Temozolomide delivered | <.001 | ||
Yes | 21.2 | 5.5 | |
No | 78.8 | 94.5 | |
Other chemotherapy delivered | <.001 | ||
Yes | 23.3 | 10.5 | |
No | 76.7 | 89.5 | |
Discharged home after index hospitalization | <.001 | ||
Yes | 52.4 | 25.7 | |
No | 47.6 | 74.3 | |
Cumulative days hospitalized after index hospitalization, ** median (IQR) | 13 (7–22) | 26 (17–41) | <.001 |
Abbreviations: GTR, gross total resection; STR, subtotal resection; IQR, interquartile range.
*Excluding the 132 patients who did not survive their initial hospitalization for glioblastoma diagnosis. All values represent percentages.
**Among all patients surviving index hospitalization.